A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer
This phase 2 portion of a phase 1/2 study examined the efficacy and safety of LY2603618, a selective checkpoint kinase 1 inhibitor, combined with pemetrexed and cisplatin (LY+Pem+Cis) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). This multicenter, randomized, controlled,...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
June 2017
|
| In: |
Lung cancer
Year: 2017, Volume: 108, Pages: 212-216 |
| ISSN: | 1872-8332 |
| DOI: | 10.1016/j.lungcan.2017.03.001 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1016/j.lungcan.2017.03.001 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0169500217302556 
|
| Author Notes: | Thomas Wehler, Michael Thomas, Christian Schumann, Joaquim Bosch-Barrera, Nuria Viñolas Segarra, Nicolas J. Dickgreber, Klaus Dalhoff, Martin Sebastian, Jesus Corral Jaime, Miriam Alonso, Scott M. Hynes, Ji Lin, Karla Hurt, Aimee Bence Lin, Emiliano Calvo, Luis Paz-Ares |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1662814534 | ||
| 003 | DE-627 | ||
| 005 | 20230426154243.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190404s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lungcan.2017.03.001 |2 doi | |
| 035 | |a (DE-627)1662814534 | ||
| 035 | |a (DE-599)KXP1662814534 | ||
| 035 | |a (OCoLC)1341207916 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Wehler, Thomas Christian |d 1975- |e VerfasserIn |0 (DE-588)13000927X |0 (DE-627)487569016 |0 (DE-576)297948288 |4 aut | |
| 245 | 1 | 2 | |a A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer |c Thomas Wehler, Michael Thomas, Christian Schumann, Joaquim Bosch-Barrera, Nuria Viñolas Segarra, Nicolas J. Dickgreber, Klaus Dalhoff, Martin Sebastian, Jesus Corral Jaime, Miriam Alonso, Scott M. Hynes, Ji Lin, Karla Hurt, Aimee Bence Lin, Emiliano Calvo, Luis Paz-Ares |
| 264 | 1 | |c June 2017 | |
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 04.04.2019 | ||
| 520 | |a This phase 2 portion of a phase 1/2 study examined the efficacy and safety of LY2603618, a selective checkpoint kinase 1 inhibitor, combined with pemetrexed and cisplatin (LY+Pem+Cis) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). This multicenter, randomized, controlled, open-label study (NCT01139775) enrolled patients with stage IV nonsquamous NSCLC and an Eastern Cooperative Oncology Group performance status ≤1. Patients were randomized (2:1) to LY+Pem+Cis or pemetrexed and cisplatin (Pem+Cis). Induction therapy comprised four 21-day cycles of 500 mg/m2 pemetrexed and 75mg/m2 cisplatin on Day 1 (both arms) and 275mg LY2603618 on Day 2 (LY+Pem+Cis arm). Maintenance therapy comprised 500mg/m2 pemetrexed on Day 1 (both arms) and 275mg LY2603618 on Day 2 (LY+Pem+Cis arm) until disease progression. The primary endpoint was progression‐free survival (PFS). Enrollment was permanently halted before target enrollment was met due to a greater number of thromboembolic events in the LY+Pem+Cis arm. Sixty-two patients were enrolled (LY+Pem+Cis, n=39; Pem+Cis, n=23). Bayesian and frequentist analysis demonstrated superior PFS in the LY+Pem+Cis arm vs the Pem+Cis arm (median [90% confidence interval]: LY+Pem+Cis, 4.7 months [4.-7.1]; Pem+Cis, 1.5 months [1.3-2.9]; P=0.022). Seven patients in the LY+Pem+Cis arm (vs 0 in the Pem+Cis arm) experienced serious thromboembolic events: pulmonary embolism (n=5), ischemic stroke (n=1), and cerebrovascular accident (n=1). Although the primary endpoint was met, the combination of LY2603618+Pem+Cis will not be further developed for treating advanced nonsquamous NSCLC due to the potential increased risk of thromboembolic events with this combination. ClinicalTrials.gov Identifier: NCT01139775. | ||
| 650 | 4 | |a Checkpoint kinase 1 | |
| 650 | 4 | |a Cisplatin | |
| 650 | 4 | |a LY2603618 | |
| 650 | 4 | |a Non-small cell lung cancer | |
| 650 | 4 | |a Pemetrexed | |
| 700 | 1 | |a Thomas, Michael |e VerfasserIn |0 (DE-588)1054438781 |0 (DE-627)79152213X |0 (DE-576)41027089X |4 aut | |
| 700 | 1 | |a Schumann, Christian |d 1972- |e VerfasserIn |0 (DE-588)129158933 |0 (DE-627)390026700 |0 (DE-576)338246959 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lung cancer |d Amsterdam [u.a.] : Elsevier, 1985 |g 108(2017), Seite 212-216 |h Online-Ressource |w (DE-627)320649733 |w (DE-600)2025812-4 |w (DE-576)264627539 |x 1872-8332 |7 nnas |a A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer |
| 773 | 1 | 8 | |g volume:108 |g year:2017 |g pages:212-216 |g extent:5 |a A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.lungcan.2017.03.001 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0169500217302556 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190404 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1054438781 |a Thomas, Michael |m 1054438781:Thomas, Michael |d 910000 |d 950000 |d 950900 |e 910000PT1054438781 |e 950000PT1054438781 |e 950900PT1054438781 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 2 | ||
| 999 | |a KXP-PPN1662814534 |e 3418084362 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["1662814534"],"doi":["10.1016/j.lungcan.2017.03.001"]},"physDesc":[{"extent":"5 S."}],"note":["Gesehen am 04.04.2019"],"relHost":[{"origin":[{"dateIssuedKey":"1985","dateIssuedDisp":"1985-","publisher":"Elsevier","publisherPlace":"Amsterdam [u.a.]"}],"recId":"320649733","type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 20.02.20"],"id":{"issn":["1872-8332"],"zdb":["2025812-4"],"eki":["320649733"]},"disp":"A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancerLung cancer","physDesc":[{"extent":"Online-Ressource"}],"pubHistory":["1.1985 -"],"language":["eng"],"part":{"extent":"5","pages":"212-216","text":"108(2017), Seite 212-216","year":"2017","volume":"108"},"title":[{"subtitle":"journal of the International Association for the Study of Lung Cancer","title":"Lung cancer","title_sort":"Lung cancer"}]}],"recId":"1662814534","origin":[{"dateIssuedDisp":"June 2017","dateIssuedKey":"2017"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"family":"Wehler","given":"Thomas Christian","role":"aut","display":"Wehler, Thomas Christian"},{"family":"Thomas","role":"aut","given":"Michael","display":"Thomas, Michael"},{"family":"Schumann","given":"Christian","role":"aut","display":"Schumann, Christian"}],"name":{"displayForm":["Thomas Wehler, Michael Thomas, Christian Schumann, Joaquim Bosch-Barrera, Nuria Viñolas Segarra, Nicolas J. Dickgreber, Klaus Dalhoff, Martin Sebastian, Jesus Corral Jaime, Miriam Alonso, Scott M. Hynes, Ji Lin, Karla Hurt, Aimee Bence Lin, Emiliano Calvo, Luis Paz-Ares"]},"title":[{"title":"A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer","title_sort":"randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer"}],"language":["eng"]} | ||
| SRT | |a WEHLERTHOMRANDOMIZED2017 | ||